title: The tumor vessel targeting agent NGR-TNF controls the different stages of the tumorigenic process in transgenic mice by distinct mechanisms.
abstract: NGR-TNF is a vascular targeting agent in advanced clinical development, coupling tumor necrosis factor-α (TNF) with the CNGRCG peptide, which targets a CD13 isoform specifically expressed by angiogenic vessels. Antitumor efficacy of NGR-TNF has been described in different transplantation tumor models. Nevertheless, the mechanism underlying its activity is not fully understood. In the wild type and in the immunodeficient (RAG-/-) RIP1-Tag2 models of multistage pancreatic carcinogenesis, we demonstrate that CD13 is highly expressed on endothelial cells of hyperplastic and angiogenic islets, whereas its expression is down regulated in tumors where it partially colocalize with pericytes.In vivoCNGRCG peptides coupled to fluorescent nanoparticles (quantum dots) bind to CD13 and colocalize with anti-CD31, in pancreatic islets. At early stage, low doses of NGR-murine (m)TNF have a direct cytotoxic effect inducing endothelial cell apoptosis, reducing vessel density and eventually inhibiting the development of angiogenic islets. At a later stage, NGR-mTNF is able to reduce tumor growth inducing vascular normalization, exclusively when treatment is carried out in the immunocompetent mice. Interestingly, NGR-mTNF-treated tumors from these mice are characterized by CD8+T cell infiltration. At molecular level, overexpression of genes involved in vessels normalization was detected only in NGR-mTNF-treated tumors from immunocompetent mice. These findings identified a new mechanism of action of NGR-mTNF, providing support for the development of new therapeutic strategies combining chemotherapy or active/adoptive immunotherapies to low dose NGR-TNF treatment.
authors.affiliation: MolMed SpA ; Milan, Italy.
authors.forename: Simona
authors.initials: S
authors.lastname: Porcellini
authors.affiliation: MolMed SpA ; Milan, Italy.
authors.forename: Claudia
authors.initials: C
authors.lastname: Asperti
authors.affiliation: MolMed SpA ; Milan, Italy.
authors.forename: Barbara
authors.initials: B
authors.lastname: Valentinis
authors.affiliation: MolMed SpA ; Milan, Italy.
authors.forename: Elena
authors.initials: E
authors.lastname: Tiziano
authors.affiliation: MolMed SpA ; Milan, Italy.
authors.forename: Patrizia
authors.initials: P
authors.lastname: Mangia
authors.affiliation: MolMed SpA ; Milan, Italy ; Vita-Salute San Raffaele University ; Milan, Italy.
authors.forename: Claudio
authors.initials: C
authors.lastname: Bordignon
authors.affiliation: MolMed SpA ; Milan, Italy.
authors.forename: Gian-Paolo
authors.initials: GP
authors.lastname: Rizzardi
authors.affiliation: MolMed SpA ; Milan, Italy.
authors.forename: Catia
authors.initials: C
authors.lastname: Traversari
keywords: TNF; angiogenesis; immune system; vascular normalization; vascular targeting